VivoSeq
Other

Capecitabine

0

Pipeline Programs↗

11

Active Trials↗

13

Companies Involved↗

Capecitabine is an early-stage landscape with 0 programs across 13 companies. The most active players are ASLAN Pharmaceuticals, GSK, Odonate Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

74/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

ASLAN Pharmaceuticals

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalO

Odonate Therapeutics, Inc.

0 programs

PreclinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalP

Processa Pharmaceuticals

0 programs

PreclinicalP

Puma Biotechnology, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

66

clinical trials

Completed32 · 48%
Unknown status12 · 18%
Terminated10 · 15%
Recruiting5 · 8%
Not yet recruiting4 · 6%
Active, not recruiting2 · 3%
Other1 · 2%

Clinical Trials

Trial Activity

66 trials

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06313463·375 enrolled
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
Recruiting·EErasmus Medical Center·N/A·NCT07114627·66 enrolled
Irinotecan Liposome in Combination With Capecitabine
Recruiting·—·N/A·NCT06578052·20 enrolled
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
Recruiting·—·Phase 1/2·NCT06776770·52 enrolled
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Recruiting·—·Phase 1/2·NCT06134375·204 enrolled
Study of the Impact of DPD Activity on the Efficacy of Capecitabine
Active, not recruiting·CCentre Antoine Lacassagne·Phase 2·NCT04198727·155 enrolled
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03448835·20 enrolled
CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE)
Not yet recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 2·NCT07254962·75 enrolled
Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC
Not yet recruiting·SSun Yat-sen University·Phase 3·NCT03503136·632 enrolled
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT07331428·25 enrolled
Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC
Not yet recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06699459·76 enrolled
Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC
Completed·National Cancer Center, Korea·Phase 2·NCT00532714·36 enrolled
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
Completed·DDutch Colorectal Cancer Group·Phase 3·NCT01918852·161 enrolled
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
Completed·AASLAN Pharmaceuticals·Phase 1·NCT02648425·31 enrolled
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
Completed·UUniversity Hospital, Limoges·Phase 4·NCT00812864·20 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)